Relapsed Or Refractory Diffuse Large B-Cell Lymphoma

Relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)

First-Line Ovarian Cancer Maintenance Therapy

Recurrent Platinum-Sensitive Ovarian Cancer

Second-Line RAS/BRAF Wild-Type Recurrent, Unresectable, Or Metastatic Colorectal Cancer

First-Line RAS/BRAF Wild-Type Left-Sided Unresectable Or Metastatic Colorectal Cancer

Newly Diagnosed Diffuse Large B-Cell Lymphoma

Second-Line Platinum-Sensitive Ovarian Cancer

Second/Third-Line Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma

First-Line PD-L1+ Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma

First-Line High Tumor Burden Follicular Lymphoma

Newly Diagnosed Diffuse Large B-Cell Lymphoma (Older Unfit/Frail)

1L Follicular Lymphoma, 1L Diffuse Large B-Cell Lymphoma

Relapsed Or Refractory Chronic Lymphocytic Leukemia

Genmab A / S develops antibody therapies for the treatment of cancer and other diseases mainly in Denmark. The company is headquartered in Copenhagen, Denmark.

GMAB · Genmab